Association of Pneumococcal Conjugate Vaccination With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Older Adult Recipients of Coronavirus Disease 2019 Vaccines: A Longitudinal Cohort Study
Among older adults who had received ≥2 COVID-19 vaccine doses, PCV13 was associated with modest protection against SARS-CoV-2 infection. Protective effects of PCV13 were greater among individuals expected to have weaker immune protection against SARS-CoV-2 infection.
Authors
- Bradley K. Ackerson (ORCID: https://orcid.org/0000-0002-0816-7345)
- Lindsay R. Grant (ORCID: https://orcid.org/0000-0002-4538-6424)
- Adriano Arguedas (ORCID: https://orcid.org/0000-0002-1659-8225)
- Joseph A. Lewnard (ORCID: https://orcid.org/0000-0002-8505-8839)
- Vennis Hong (ORCID: https://orcid.org/0000-0002-6060-8419)
- Sara Y. Tartof (ORCID: https://orcid.org/0000-0003-2336-8476)
- Katia J. Bruxvoort (ORCID: https://orcid.org/0000-0001-8277-2431)
- Magdalena E Pomichowski (ORCID: https://orcid.org/0009-0004-7280-9084)
- Luis Jódar (ORCID: https://orcid.org/0000-0003-1246-530X)
- Alejandro Cané (ORCID: https://orcid.org/0000-0003-0778-6862)
- Bradford D Gessner
Institutions
- Kaiser Permanente (US)
- Pfizer (United States) (US)
- University of Alabama at Birmingham (US)
- University of California, Berkeley (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1093/infdis/jiae387
- Citations
- 4
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 1.55
Funders
- Pfizer